The primary objective of Project 1 is to define the mechanisms of functional impairment of HCV-specific CDS T cells associated with viral persistence. While viral escape mutations within T cell epitopes occur in HCV immune evasion, a significant proportion of CDS T cells in chronically infected subjects recognize HCV epitopes that do not demonstrate escape mutations. It is thus likely that functional impairment of CDS cells specific for nonescaped epitopes is an additional important factor in HCV persistence. We propose that a comprehensive comparative analysis of HCV-specific CDS T cell phenot5TDe and function among patients who clear HCV infection versus those who do not, and between T cells recognizing epitopes that undergo substitution and those that do not will reveal specific molecular and cellular mechanisms of T cell unresponsiveness relevant to viral persistence. Specifically, we aim l)To perform a set of in vitro fiinctional analyses assessing the capacity of HCV specific CDS T cells of various previously characterized phenotj^jes to produce relevant effector cj^okines and to perform killer functions and 2)To develop and characterize an in vivo cj^otoxic lymphocyte (CTL) assay for functional analysis of tetramer+ HCV specific CDS cells using adoptive transfer into an established NOD/SCID/--/- system. This will allow us to directly analyze the in vivo functional effects of antibodies and/or cytokines targeted at potentially relevant cell membrane receptors on human HCV specific CDS T cells. Using specific antagonist antibodies, candidate molecular determinants of CDS T cell unresponsiveness will be interrogated in this novel in vivo system in which human T cells from patients are adoptively transferred into receptive immunodeficient mice. Outcomes of this interrogation will have direct translational relevance to the immunotherapy of chronic HCV infection as well as enhancing understanding of T cell impairment associated with persistent infection. Results of studies of humoral immune responses from Project 2 will be integrated to expand knowledge of the interplay between humoral and cellular immune responses to HCV in humans. We have already demonstrated that we can obtain the critical specimens required for this investigation and will be able to conduct unique longitudinal studies of adaptive immune responses in acute HCV.

Public Health Relevance

Project 1 is focused on understanding how T cells, an important arm of the immune system, are rendered ineffecfive in people who acquire HCV infecfion by comparing the function of T cells in people who control their HCV infection and those who do not. The goal is to understand the factors that permit T cell control ofHCV infection to provide new means of treating people who did not successfully control the infection on their own,

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI088791-01
Application #
7919765
Study Section
Special Emphasis Panel (ZAI1-BP-M (J1))
Project Start
2010-04-15
Project End
2015-03-31
Budget Start
2010-04-15
Budget End
2011-03-31
Support Year
1
Fiscal Year
2010
Total Cost
$184,723
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Mankowski, Madeleine C; Kinchen, Valerie J; Wasilewski, Lisa N et al. (2018) Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proc Natl Acad Sci U S A 115:E82-E91
Kinchen, Valerie J; Cox, Andrea L; Bailey, Justin R (2018) Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine? Trends Microbiol 26:854-864
Esmaeili, Aryan; Mirzazadeh, Ali; Morris, Meghan D et al. (2018) The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative. Clin Infect Dis 66:20-28
Kinchen, Valerie J; Zahid, Muhammad N; Flyak, Andrew I et al. (2018) Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. Cell Host Microbe 24:717-730.e5
Kinchen, Valerie J; Bailey, Justin R (2018) Defining Breadth of Hepatitis C Virus Neutralization. Front Immunol 9:1703
Rose, Rebecca; Lamers, Susanna L; Massaccesi, Guido et al. (2018) Complex patterns of Hepatitis-C virus longitudinal clustering in a high-risk population. Infect Genet Evol 58:77-82
Ke, Ruian; Li, Hui; Wang, Shuyi et al. (2018) Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence. Proc Natl Acad Sci U S A 115:E7139-E7148
Bailey, Justin R; Barnes, Eleanor; Cox, Andrea L (2018) Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. Gastroenterology :
Morris, Meghan D; Shiboski, Stephen; Bruneau, Julie et al. (2017) Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. Clin Infect Dis 64:860-869
Vergara, C; Thio, C; Latanich, R et al. (2017) Genetic basis for variation in plasma IL-18 levels in persons with chronic hepatitis C virus and human immunodeficiency virus-1 infections. Genes Immun 18:82-87

Showing the most recent 10 out of 59 publications